Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Jinqiao is a Traditional Chinese Medicine (TCM) formulation developed by the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, specifically designed for pediatric use. It is primarily indicated for the treatment of influenza and upper respiratory tract infections characterized by wind-heat patterns in TCM theory, which include symptoms such as fever, sore throat, and cough. The formulation typically contains herbal ingredients like *Lonicera japonica* (honeysuckle) and *Forsythia suspensa*, which are known for their anti-inflammatory, anti-pyretic, and anti-viral properties. In China, it is recognized as a hospital preparation (医院制剂), a specific regulatory category for drugs developed and used within a hospital setting, and it is widely utilized in clinical practice for children during seasonal influenza outbreaks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Jinqiao.